Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Among authors: olson a. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN; Reach Study Group. Thayu M, et al. Among authors: olson a. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1378-84. doi: 10.1016/j.cgh.2008.07.010. Clin Gastroenterol Hepatol. 2008. PMID: 19081527 Clinical Trial.
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.
Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano RN. Crandall W, et al. Among authors: olson a. J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):183-90. doi: 10.1097/MPG.0b013e3181a70f21. J Pediatr Gastroenterol Nutr. 2009. PMID: 19561542 Clinical Trial.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Sandborn WJ, et al. Among authors: olson a. Gastroenterology. 2009 Oct;137(4):1250-60; quiz 1520. doi: 10.1053/j.gastro.2009.06.061. Epub 2009 Jul 28. Gastroenterology. 2009. PMID: 19596014 Clinical Trial.
Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Rutgeerts P, et al. Among authors: olson a. N Engl J Med. 2005 Dec 8;353(23):2462-76. doi: 10.1056/NEJMoa050516. N Engl J Med. 2005. PMID: 16339095 Free article. Clinical Trial.
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. Lichtenstein GR, et al. Among authors: olson ad. Aliment Pharmacol Ther. 2009 Aug;30(3):210-26. doi: 10.1111/j.1365-2036.2009.04027.x. Epub 2009 Apr 21. Aliment Pharmacol Ther. 2009. PMID: 19392858 Clinical Trial.
1,527 results